摘要
单克隆抗体作为抗癌药物研究已取得重要进展,人源化抗体技术的成熟,为单克隆抗体抗癌药物在临床上应用奠定了基础。单克隆抗体再次成为抗肿瘤药物研究的聚焦点,并且展现了良好诱人的市场前景。我国在抗肿瘤单克隆抗体研发方面也取得了重大进展。
It has taken a considerable progress in monoclonal antibodies as anticancer drugs.The development of humanized antibodies provides a promise for clinical application of mono-clonal antibodies as anticancer drugs.Monoclonal antibody has become a hotspot in anticancer drugs again and displayed a brilliant prospect in market.Our country is making great progress in this field.
出处
《中国肿瘤》
CAS
2003年第9期523-525,共3页
China Cancer
